Alexza Pharmaceuticals receives marketing authorization for Adasuve in EU Alexza Pharmaceuticals announced that the European Commission has granted marketing authorization for Adasuve. In the European Union, Adasuve, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The Adasuve marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that Adasuve is administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects.
Alexza Pharmaceuticals initiates Phase 2a study of AZ-002 in epilepsy Alexza Pharmaceuticals has initiated a Phase 2a study of AZ-002 - Staccato alprazolam -, which is being developed for the management of epilepsy in patients with acute repetitive seizures. ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs. Alexza expects to announce results from this study in 1H15.